Most pharmaceutical packaging design problems are found too late. The artwork is signed off, the cartons are printed, and the first thing anyone discovers is that the Braille sits across a crease, the coding panel is under a gloss varnish, or the strength is set in a point size the assessor will not accept. At that stage every option is expensive.

Pharmaceutical packaging design has to satisfy three things at once: the statutory content, the MHRA's expectations about how that content reads, and what the packing line can physically produce and verify. A design that meets the first two and fails the third still costs a launch date.

This article is about the second and third. The statutory particulars themselves, including reduced content for blisters and small containers, Braille and leaflet requirements, are listed in our guide to pharmaceutical labelling requirements in the UK, and the licensing and serialisation framework in our article on pharmaceutical packaging regulations in the UK. Take the content list as given, and start from how it is presented.

Why MHRA best practice guidance behaves like law

The MHRA publishes Best Practice Guidance on Labelling and Packaging of Medicines. It is guidance rather than legislation, but assessors apply it during artwork review and inspectors raise it, so treat it as an expectation. Most artwork that comes back comes back on guidance points, not missing particulars.

Information hierarchy and reading order

Group the critical information. The name, strength and pharmaceutical form and the route of administration should sit together in one block, in a consistent position, so a user takes them in as a set rather than assembling them from three corners of a panel.

Then think about reading order in the real setting. A pharmacist picking from a shelf reads whichever face is presented, in about a second, looking for name and strength. If the strength appears on the front face but not the side or the top, the pack is being selected on brand colour alone. Put the identifying set where it can be read from every orientation the pack is stored in, including on its end in a drawer.

State the route positively. "For oral use" works better than a warning about the routes that do not apply. Negatives are misread under time pressure, and a design that relies on the reader processing one has added a step where errors happen.

Legibility: font size, spacing and contrast

Minimum font sizes are the visible half of legibility. Line spacing is the half that gets squeezed, usually late, when a warning is added and nobody wants to redraw the panel. Tightly leaded text is a legibility failure even when every particular is correctly sized.

Contrast matters as much as size. Fine reversed-out type on a mid-tone background, metallic inks under dispensary lighting and low-contrast tints all reduce readability for the users least able to compensate. Design for an older patient without reading glasses, not for a studio monitor.

Colour and look-alike, sound-alike risk

Colour may support differentiation. It must never be the only cue distinguishing 5 mg from 50 mg. Colour-coding by strength alone trains users to select by colour, which works until a substrate changes, a print run drifts, or a competitor adopts the same palette.

Look-alike, sound-alike risk needs assessing across your own portfolio and against competitor products likely to sit on the same shelf. If your 2.5 mg and 25 mg packs are indistinguishable at arm's length, the design has created a selection error waiting to happen. Vary more than one attribute: position, typography, panel layout, pack format.

Whitespace as a safety feature

Treat whitespace as functional rather than wasted. Dense panels slow reading and bury the information that prevents an error. Cramming an extra language or warning into a spare millimetre degrades everything around it. Where the leaflet can carry the detail, let it, and keep the pack face for identification.

Blister foil and QR codes

Repeat the name and strength over each blister pocket, or frequently enough along the foil that identity survives when a strip is cut up. Patients are handed cut strips and keep the last doses loose in a bag; the design has to assume that rather than an intact card.

Use QR codes only where they lead to information consistent with the approved product information. A code pointing at a marketing page or an uncontrolled microsite is not acceptable, and the destination needs to stay under change control for the life of the pack.

Where a presentation changes significantly, user testing or bridging against a previously tested leaflet is normally expected to show the revised design is still readable and comprehensible.

Where pharmaceutical packaging design becomes a manufacturing constraint

This is the part that gets missed. Once artwork is approved, every design decision has become a manufacturing constraint, and the packing line has to live with it.

Braille embossing needs clearance from creases, glue flaps and varnished areas, and the dot profile has to survive erecting, closing and transport. Varnish and coating choices determine whether inkjet or laser coding will adhere and stay legible, and whether an anti-tamper label will stick. Reserved space and print surface quality determine whether a 2D DataMatrix can be printed and verified to grade, which matters for any export market where serialisation applies. Board grade, grain direction and carton dimensions determine erecting speed and whether standard cartoner change parts will run the pack at all. Dark solids across creasing lines crack. Fine reversed-out text closes up on absorbent board. A leaflet one fold too thick will jam a feeder.

None of that is visible in a PDF proof. It shows up on the line, in a vision system reject rate, or in a batch that cannot be certified.

The cost of finding out late

An artwork change before print costs a revision cycle. The same change after 200,000 cartons are delivered costs the components, the rework or scrap decision, the change control record and the slot in the packing schedule, and it usually lands on a launch date set before anyone looked at a cutter guide.

The fix is sequencing rather than effort. Bring the packer in while the design is still a layout: check the reserved areas for coding, confirm the Braille panel, agree the varnish map, and trial the component on the equipment that will run it. Central Pharma reviews artwork and cutter guides against the actual line, feeds manufacturability comments back before sign-off, and verifies the printed component against the approved proof at goods-in and at line start.

Key takeaways

• MHRA best practice guidance is not legislation, but it is applied at assessment and inspection, and most returned artwork fails on guidance points rather than missing particulars.
• Group name, strength and route in one block, state the route positively, and place the identifying set so it reads from every orientation the pack is stored in.
• Colour may support differentiation but never replace it, and look-alike, sound-alike risk should be assessed against competitor packs as well as your own range.
• Repeat name and strength along blister foil so identity survives a cut strip, and point QR codes only at controlled, approved information.
• Every approved design decision becomes a manufacturing constraint, so validate Braille placement, varnish maps, coding areas and board grade before artwork is signed off.

Talk to Central Pharma about your packaging design before you sign it off

Central Pharma has filled and packed for the pharmaceutical, medical device, cell and gene therapy and healthcare sectors since 2006, from a 267,000 sq ft MHRA-licensed site in Bedford with three Qualified Persons and QP release to more than 60 countries. Our role in pharmaceutical packaging design is the licensed one: reviewing artwork for regulatory content, Braille, coding and serialisation readiness, qualifying the pack on the equipment that will make it, and telling your design team what will not run while changing it is still cheap. To get that input early, contact us.

To stay informed on our latest thinking and technology developments, follow us on LinkedIn.

Contact Us Today

View all news